Search | CATIE - Canada's source for HIV and hepatitis C information

Jump to Navigation Jump to Content

Sort Results

Filter by Specific Population

Women (remove)

Filter by Topic

Treatment (remove)
- HIV drugs (remove)
  - Dolutegravir (Tivicay) (remove)
  - Atazanavir (Reyataz) (1)
  - Raltegravir (Isentress, Isentress HD) (1)
- Side effects (1)
Reproductive and maternal health (5)

Filter by Infection

HIV (remove)

Filter by Resource Category

Research summary (6)

Search results

Current filters: HIV, Treatment, HIV drugs, Women, Dolutegravir (Tivicay)

6 search results

Decreasing the risk of neural tube defects with dolutegravir: From TreatmentUpdate 233
2019, CATIE
Research summary - Webpage
Agencies issue caution about use of dolutegravir by pregnant HIV-positive women: 2018, CATIE
Research summary - Webpage
Dolutegravir in women: From TreatmentUpdate 218
2016, CATIE
Research summary - Webpage
U.S. study reviews use and impact of integrase inhibitors in pregnancy: 2016, CATIE
Research summary - Webpage
A successful pregnancy and birth outcome with dolutegravir-based ART: From TreatmentUpdate 212
2016, CATIE
Research summary - Webpage
Dolutegravir—Interaction with atazanavir during pregnancy: From TreatmentUpdate 212
2016, CATIE
Research summary - Webpage

Production of this Web site has been made possible through a financial contribution from the Public Health Agency of Canada.

We comply with the HONcode standard for trustworthy health information: verify here.

Please note that some content on this website contains language, information and images related to sexuality and drug use, and may not be intended for people of all ages. CATIE ensures that these resources, developed to help prevent the transmission of HIV, hepatitis C and other infections, are written and reviewed by health experts for content accuracy.